A one-size-fits-all strategy is not the best approach for the development of a chemistry, manufacturing, and controls program.
Wayland Rushing
Advertisement
Wayland Rushing, PhD, is director, scientific affairs for Eurofins, BioPharma Product Testing.
Articles by Wayland Rushing
Advertisement
Latest Updated Articles
Designing Phase-Appropriate CMC Analytical ProgramsAugust 1st 2019
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Updates Master Protocol: What Developers Need to Know
2
IPEC’s Excipient Information Package: A Standardized Communication Platform for Sharing Excipient Information as an Alternative to Questionnaires
3
Pharma Fundamentals: Hold Times in Biopharmaceuticals
4
Merck KGaA Launches Saturnus Bio; Announces Awards
5